戻る Agenda
Session 5, Part I: Panel Discussion - Implementation, Barriers & Opportunities
Session Chair(s)
Mireille Muller, DRSC, PHD, MSC
Regulatory Policy & Intelligence Director
Novartis Pharma AG, Switzerland
Session 5, Part I: Panel Discussion - Implementation, Barriers & Opportunities
Speaker(s)
Session 5, Part I: Panel Discussion - Implementation, Barriers & Opportunities
Mathieu Boudes, PHD
Montsouris Consilium, France
Patient Engagement Director
Panel discussion with Q&A
Francesco Pignatti, MD
European Medicines Agency, Netherlands
Scientific Adviser for Oncology
Contributing Panelist
Laura Lee Johnson, PHD
FDA, United States
Director, Division of Biometrics III, Office of Biostatistics, OTS, CDER
Contributing Panelist
Bennett Levitan, MD, PHD
Johnson & Johnson, United States
Executive Director, Benefit-Risk Assessment / Epidemiology
Contributing Panelist
Michelle Tarver, MD, PHD
FDA, United States
Deputy Center Director for Transformation, CDRH
Contributing Panelist
Irina Cleemput, PHD
Belgian Health Care Knowledge Centre (KCE), Belgium
Scientific Programme Director
Contributing Panelist
Valentina Strammiello, MA
European Patients' Forum, Belgium
Director of Programmes
Contributing Panelist
Menia Koukougianni, MBA
NGO KARKINAKI AWARENESS FOR CHILDHOOD AND ADOLESCENT CANCER, Greece
Patient Representative